American Herbal Products Association (AHPA) > AHPA Resources > Regulations

AHPA expresses support for synthetic cannabinoids being placed into schedule I

February 2017: AHPA submits comments to DEA

The American Herbal Products Association (AHPA) expressed strong support for the Drug Enforcement Agency (DEA) using its temporary scheduling authority to place synthetic cannabinoids into schedule I in comments submitted to the agency.

IADSA update on international supplement regulations

IADSA December 2016 Newsflash

This issue of the IADSA Newsflash includes an update on the Association of Southeast Asian Nations (ASEAN) Agreement on Regulatory Framework for Health Supplements deadline for implementation, which will be pushed back to March 2023.

AHPA submits comments to FDA on revised NDI draft guidance

December 2016: Draft NDI guidance fails to achieve FDA's stated goals and is contrary to intent of the law

In comments submitted to the Food and Drug Administration (FDA), the American Herbal Products Association (AHPA) expressed concern that the latest revision of draft guidance for New Dietary Ingredients (NDIs) is unlikely to achieve FDA's stated goals and is contrary to the intent of the law in numerous areas.

AHPA submits comments to DEA on potential impacts of scheduling herbal constituents

December 2016: DEA should avoid restricting research on new medical uses, health benefits, or other uses for botanicals

In comments submitted last week to the Drug Enforcement Agency (DEA), the American Herbal Products Association (AHPA) urged the agency to refrain from using its authority to effectively remove a plant from the existing marketplace because naturally occurring constituents become scheduled under the Controlled Substances Act (CSA).

AHPA submits comments to FTC regarding consumer perceptions of "organic" claims

December 2016: Many personal care products and dietary supplements are produced in compliance with USDA's National Organic Progam

AHPA stressed that non-food products, including personal care products, may be agricultural products that can comply with the United States Department of Agriculture (USDA) National Organic Program (NOP).

AHPA submits vinpocetine comments to FDA

November 2016: HHS Secretary has authority to create exceptions to dietary supplement definition

The American Herbal Products Association (AHPA) recommends the Secretary of Health and Human Services (HHS) consider initiating rulemaking to declare vinpocetine to be lawful dietary ingredient in comments submitted to the Food and Drug Administration (FDA).

AHPA Presents at Korea-China Joint International Phytonutrient Symposium

AHPA President Michael McGuffin presents overview of regulatory landscape for botanical raw materials

AHPA President Michael McGuffin presented an overview of U.S. regulations for botanical raw materials at the 2016 Korea-China Joint International Phytonutrient Symposium organized jointly by the Korean Society of Food Science and Technology (KoSFoST) and the Chinese Nutrition Society and held on October 27 in Seoul, Korea.

Update on international supplement regulations

IADSA October 2016 Newsflash

IADSA is an association focused on the globalization of food supplement markets and regulatory challenges. This issue of the IADSA Newsflash includes an update on the European Commission (EC) request of the European Food Safety Authority (EFSA) to provide a scientific opinion on the safety of green tea catechins with a proposed deadline of October 2017.

AHPA expresses concern about DEA using emergency scheduling authority to temporarily classify herb as schedule I substance

September 2016: AHPA requests DEA to delay action

The American Herbal Products Association (AHPA) sent a letter to the U.S. Drug Enforcement Agency (DEA) urging the agency to reconsider using its emergency scheduling authority to temporarily place constituents of the herb kratom into schedule I of the Controlled Substances Act (CSA).

FDA Seeks Comment on Tentative Conclusion that Vinpocetine Is not a Dietary Ingredient

FDA maintains vinpocetine is a synthetic compound

A Food and Drug Administration (FDA) notice scheduled to be published tomorrow in the Federal Register requests comments on the agency's tentative conclusion that vinpocetine is not a dietary ingredient and is excluded from the definition of a dietary supplement.

Government Advocacy

Text/HTML

Recent AHPA Advocacy

EasyDNNNews